Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate

Gyre Therapeutics (NASDAQ: GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 200 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $30.600 million which missed the analyst consensus estimate of $32.930 million by 7.08 percent. This is a 20.06 percent increase over sales of $25.488 million the same period last year.